The Nonclinical Safety Evaluation of the Anticancer Drug Atragen® (Liposomal All-Trans-Retinoic Acid)
- 1 January 2000
- journal article
- research article
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 19 (1) , 33-42
- https://doi.org/10.1080/109158100225024
Abstract
ATRAGEN® is a liposome-encapsulated intravenous (IV) formulation of the anticancer drug all-trans-retinoic acid (tretinoin). Retinoids as a class of compounds p...Keywords
This publication has 7 references indexed in Scilit:
- PATHOGENESIS AND MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIAAnnual Review of Medicine, 1996
- Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)New England Journal of Medicine, 1991
- Subchronic toxicity of all-trans-retinoic acid and retinylidene dimedone in Sprague-Dawley ratsToxicology, 1984
- Preclinical and Clinical Toxicology of Selected RetinoidsPublished by Elsevier ,1984
- Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observationsBlood, 1983
- Comparative toxicity of oral all-trans-retinoic acid and the aromatic retinoids Ro 10-9359 and Ro 12-7554 in rats: Hematologic and biochemical studiesDrug Development Research, 1983
- Blood Level Studies of All-trans- and 13-cis-Retinoic Acids in Rats Using Different FormulationsJournal of Pharmaceutical Sciences, 1982